vs

Side-by-side financial comparison of Array Technologies, Inc. (ARRY) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $226.0M, roughly 1.2× Array Technologies, Inc.). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs -17.9%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 21.4%).

ATI Technologies Inc. was a Canadian semiconductor technology corporation based in Markham, Ontario, that specialized in the development of graphics processing units and chipsets. Founded in 1985, the company listed publicly in 1993 and was acquired by AMD in 2006. As a major fabless semiconductor company, ATI conducted research and development in-house and outsourced the manufacturing and assembly of its products. With the decline and eventual bankruptcy of 3dfx in 2000, ATI and its chief ri...

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

ARRY vs ASND — Head-to-Head

Bigger by revenue
ASND
ASND
1.2× larger
ASND
$267.3M
$226.0M
ARRY
Growing faster (revenue YoY)
ASND
ASND
+60.2% gap
ASND
42.3%
-17.9%
ARRY
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
21.4%
ARRY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARRY
ARRY
ASND
ASND
Revenue
$226.0M
$267.3M
Net Profit
Gross Margin
8.6%
90.5%
Operating Margin
-65.5%
Net Margin
Revenue YoY
-17.9%
42.3%
Net Profit YoY
EPS (diluted)
$-1.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARRY
ARRY
ASND
ASND
Q4 25
$226.0M
$267.3M
Q3 25
$393.5M
$230.7M
Q2 25
$362.2M
$170.7M
Q1 25
$302.4M
$109.0M
Q4 24
$275.2M
$187.8M
Q3 24
$231.4M
$62.5M
Q2 24
$255.8M
$38.9M
Q1 24
$153.4M
$103.6M
Net Profit
ARRY
ARRY
ASND
ASND
Q4 25
Q3 25
$33.5M
$-65.9M
Q2 25
$43.3M
$-42.0M
Q1 25
$16.7M
$-102.2M
Q4 24
Q3 24
$-141.4M
$-107.1M
Q2 24
$25.7M
$-118.1M
Q1 24
$2.2M
$-141.5M
Gross Margin
ARRY
ARRY
ASND
ASND
Q4 25
8.6%
90.5%
Q3 25
26.9%
89.5%
Q2 25
26.8%
80.1%
Q1 25
25.3%
82.6%
Q4 24
28.5%
91.9%
Q3 24
33.8%
80.6%
Q2 24
33.6%
68.2%
Q1 24
35.9%
92.1%
Operating Margin
ARRY
ARRY
ASND
ASND
Q4 25
-65.5%
Q3 25
11.6%
5.1%
Q2 25
12.8%
-33.5%
Q1 25
9.0%
-103.2%
Q4 24
-51.7%
Q3 24
-57.3%
-167.3%
Q2 24
15.5%
-370.2%
Q1 24
5.5%
-51.2%
Net Margin
ARRY
ARRY
ASND
ASND
Q4 25
Q3 25
8.5%
-28.5%
Q2 25
11.9%
-24.6%
Q1 25
5.5%
-93.7%
Q4 24
Q3 24
-61.1%
-171.5%
Q2 24
10.0%
-303.9%
Q1 24
1.4%
-136.6%
EPS (diluted)
ARRY
ARRY
ASND
ASND
Q4 25
$-1.06
Q3 25
$0.12
Q2 25
$0.19
Q1 25
$0.02
Q4 24
$-0.94
Q3 24
$-1.02
Q2 24
$0.08
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARRY
ARRY
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$244.4M
$665.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-206.3M
$-175.8M
Total Assets
$1.5B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARRY
ARRY
ASND
ASND
Q4 25
$244.4M
$665.3M
Q3 25
$221.5M
$582.2M
Q2 25
$377.3M
$533.6M
Q1 25
$348.3M
$559.4M
Q4 24
$363.0M
$604.3M
Q3 24
$332.4M
$675.6M
Q2 24
$282.3M
$279.4M
Q1 24
$287.6M
$345.9M
Stockholders' Equity
ARRY
ARRY
ASND
ASND
Q4 25
$-206.3M
$-175.8M
Q3 25
$-46.7M
$-188.0M
Q2 25
$-70.9M
$-202.6M
Q1 25
$-97.8M
$-205.0M
Q4 24
$-118.1M
$-114.2M
Q3 24
$64.5M
$-105.1M
Q2 24
$200.0M
$-346.8M
Q1 24
$231.2M
$-257.2M
Total Assets
ARRY
ARRY
ASND
ASND
Q4 25
$1.5B
$1.4B
Q3 25
$1.6B
$1.2B
Q2 25
$1.5B
$1.2B
Q1 25
$1.4B
$1.1B
Q4 24
$1.4B
$1.3B
Q3 24
$1.6B
$1.2B
Q2 24
$1.7B
$819.0M
Q1 24
$1.6B
$866.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARRY
ARRY
ASND
ASND
Operating Cash FlowLast quarter
$43.6M
$58.2M
Free Cash FlowOCF − Capex
$36.2M
FCF MarginFCF / Revenue
16.0%
Capex IntensityCapex / Revenue
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$79.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARRY
ARRY
ASND
ASND
Q4 25
$43.6M
$58.2M
Q3 25
$27.4M
Q2 25
$43.8M
Q1 25
$-13.1M
$-15.5M
Q4 24
$57.6M
$-330.7M
Q3 24
$44.9M
Q2 24
$4.0M
Q1 24
$47.5M
$-109.7M
Free Cash Flow
ARRY
ARRY
ASND
ASND
Q4 25
$36.2M
Q3 25
$21.9M
Q2 25
$37.2M
Q1 25
$-15.4M
Q4 24
$55.9M
Q3 24
$43.9M
Q2 24
$1.8M
Q1 24
$45.1M
FCF Margin
ARRY
ARRY
ASND
ASND
Q4 25
16.0%
Q3 25
5.6%
Q2 25
10.3%
Q1 25
-5.1%
Q4 24
20.3%
Q3 24
19.0%
Q2 24
0.7%
Q1 24
29.4%
Capex Intensity
ARRY
ARRY
ASND
ASND
Q4 25
3.3%
Q3 25
1.4%
Q2 25
1.8%
Q1 25
0.8%
Q4 24
0.6%
Q3 24
0.5%
Q2 24
0.8%
Q1 24
1.6%
Cash Conversion
ARRY
ARRY
ASND
ASND
Q4 25
Q3 25
0.82×
Q2 25
1.01×
Q1 25
-0.78×
Q4 24
Q3 24
Q2 24
0.15×
Q1 24
21.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARRY
ARRY

Array Legacy Operations Segment$212.0M94%
STI Operations Segment$14.0M6%

ASND
ASND

Segment breakdown not available.

Related Comparisons